Changes in Beneficial Ownership · 4
SAB Biotherapeutics, Inc.
SABSNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-09-17
- Issuer
- SAB Biotherapeutics, Inc.
- Issuer CIK
- 0001833214
- Trading symbol
- SABS
Reporting owner 1
- Name
- Kropotova Alexandra
- Reporting owner CIK
- 0001825323
- Relationship
- Officer
- Officer title
- CHIEF MEDICAL OFFICER
- Address
- 777 W 41ST STREET, SUITE 401, MIAMI BEACH, FL, 33140
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-09-17 | F · Form 4 | 473[F1] | D | [F1] | 41,853[F2][F3] | D |
Table key
- F · Form 4
- Securities delivered or withheld for exercise price or tax liability under Rule 16b-3
- D
- Direct
Footnotes
- F1
- Represents shares of the Issuer's common stock ("Common Stock") withheld to statisfy tax withholding requirements on the vesting of the Issuer's restricked stock units ("RSUs").↩ 1↩ 2
- F2
- Includes 38,402 shares of Common Stock and 3,433 shares of Common Stock which remain subject to vesting of RSUs granted under the Issuer's 2021 Equity Incentive Plan, as amended.↩ 1
- F3
- Each RSU represents a contingent right to receive one share of Common Stock.↩ 1
Signature 1
- Signed
- /s/ Alexandra Kropotova
- Date
- 2026-09-18
Company context
SAB BIO is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. Using advanced genetic engineering and antibody science, SAB BIO developed a proprietary technology which holds the potential to generate additional novel therapeutic candidates utilizing the human immune response, without the need for human donors or convalescent plasma. SAB BIO has optimized genetic engineering in the development of transchromosomic cattle, or Tc-Bovine, to produce hIgG. SAB BIO’s drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, hIgGs that can address a wide range of serious unmet needs in human diseases. The Company’s lead candidate, SAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. SAB-142 is currently being evaluated in newly diagnosed Stage 3 autoimmune T1D patients in a registrational Phase 2b clinical trial called SAFEGUARD. For more information, visit www.sab.bio.
Current securities
Recent company filings
- Other EventsOct 13, 2026
- 424B3 filingAug 21, 2026
- SCHEDULE 13G/A - filed by PERCEPTIVE ADVISORS LLC regarding SAB Biotherapeutics, Inc.Aug 14, 2026
- SCHEDULE 13G/A - filed by Caligan Partners LP regarding SAB Biotherapeutics, Inc.Aug 14, 2026
- SCHEDULE 13G/A - filed by Commodore Capital LP regarding SAB Biotherapeutics, Inc.Aug 14, 2026